Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease

• Published in: Proteome science Vol. 16; no. 1; p. 4
• Main Authors: Spanos, Christos, Maldonado, Elaina M, Fisher, Ciarán P, Leenutaphong, Petchpailin, Oviedo-Orta, Ernesto, Windridge, David, Salguero, Francisco J, Bermúdez-Fajardo, Alexandra, Weeks, Mark E, Evans, Caroline, Corfe, Bernard M, Rabbani, Naila, Thornalley, Paul J, Miller, Michael H, Wang, Huan, Dillon, John F, Quaglia, Alberto, Dhawan, Anil, Fitzpatrick, Emer, Moore, J Bernadette
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14-02-2018; BioMed Central; BMC
• Subjects: Biological markers; Development and progression; Fatty liver; Genetic aspects; Glyoxalase; iTRAQ; Methylglyoxal; Non-alcoholic fatty liver disease; Proteomics; United Kingdom; iTRAQ; Methylglyoxal; Non-alcoholic fatty liver disease; Glyoxalase; Proteomics
• ISSN: 1477-5956; 1477-5956
• DOI: 10.1186/s12953-018-0131-y

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. However, its molecular pathogenesis is incompletely characterized and clinical biomarkers remain scarce. The aims of these experiments were to identify and characterize liver protein alterations in an animal model of early, diet-related, liver injury and to assess novel candidate biomarkers in NAFLD patients.
Liver membrane and cytosolic protein fractions from high fat fed apolipoprotein E knockout (ApoE
) animals were analyzed by quantitative proteomics, utilizing isobaric tags for relative and absolute quantitation (iTRAQ) combined with nano-liquid chromatography and tandem mass spectrometry (nLC-MS/MS). Differential protein expression was confirmed independently by immunoblotting and immunohistochemistry in both murine tissue and biopsies from paediatric NAFLD patients. Candidate biomarkers were analyzed by enzyme-linked immunosorbent assay in serum from adult NAFLD patients.
Through proteomic profiling, we identified decreased expression of hepatic glyoxalase 1 (GLO1) in a murine model. GLO1 protein expression was also found altered in tissue biopsies from paediatric NAFLD patients. In vitro experiments demonstrated that, in response to lipid loading in hepatocytes, GLO1 is first hyperacetylated then ubiquitinated and degraded, leading to an increase in reactive methylglyoxal. In a cohort of 59 biopsy-confirmed adult NAFLD patients, increased serum levels of the primary methylglyoxal-derived advanced glycation endproduct, hydroimidazolone (MG-H1) were significantly correlated with body mass index (
 = 0.520,
 < 0.0001).
Collectively these results demonstrate the dysregulation of GLO1 in NAFLD and implicate the acetylation-ubquitination degradation pathway as the functional mechanism. Further investigation of the role of GLO1 in the molecular pathogenesis of NAFLD is warranted.